Investigating transmission of GBS to newborn babies in Malawi

Genetic fingerprinting techniques to investigate the relationship between GBS bacteria carried by mothers and those causing severe GBS disease in newborns in Malawi

Researchers
Prof Rob Heyderman, Prof Neil French, Dr Queen Dube, Dr Emma Wall, Dr Macpherson Mallewa.
Start Date
01 Feb 2014
Category
Prevention
Organisation
Liverpool School of Tropical Medicine, Blantyre, Malawi, University of Liverpool, Liverpool UK

What is this project about? 

This project aims to understand how bacteria called GBS (Group B Streptococcus), which cause meningitis and severe blood poisoning, are transmitted to newborn babies in Africa. Professor Heyderman and his team will use state-of the art genetic fingerprinting techniques to investigate the relationship between GBS bacteria carried by mothers and those causing severe GBS disease in newborns in Malawi. They will also use this information to work out whether GBS transfer from mother to child occurs only around the time of birth or can happen later in the first month of life which is the main danger period for severe GBS infection in Malawi.

The specialist clinical team will recruit and follow-up pregnant women and their babies at a local health-centre in Blantyre, Malawi to provide a collection of paired mother-baby GBS samples that will add to an existing large collection of GBS samples. Using genetic fingerprinting, they will then compare mother and child GBS, to better understand the origin of disease-causing GBS.

Why is it important?

The last ten years have seen major improvements in the number of deaths in children under 5 years old in many regions of Africa. However, newborn deaths are still unacceptably high. GBS meningitis and severe bloodstream infection are large contributors to this very high disease burden in Malawi and many other resource-poor settings. Urgent action is therefore needed to improve this situation and prevention of GBS is therefore an important public health priority. GBS could be prevented by giving antibiotics to mothers around the time of birth (called IAP) or vaccinating mothers against GBS. Vaccines are currently being tested but it may be 5-10 years before an effective vaccine can be introduced into routine programmes. For either vaccines or IAP to be implemented effectively, we need to know where the GBS that causes life-threatening disease in newborns comes from. This project will address this question.

What is genetic fingerprinting?

Each strain of GBS bacteria carries a unique genetic code, so that some strains inherit an ability to transfer especially easily from mother to child or to cause disease.

This unique code means that each strain has a fingerprint and can be distinguished from others. This project will use state of the art techniques to look at the genetic code of GBS from both mothers and their children to see which strains are being transmitted.

Potential outcomes

This project will produce data that will be vital for understanding GBS meningitis and severe bloodstream infections in developing countries, as well as the likely benefits of IAP. It will also provide crucial data for the design and implementation of novel GBS vaccines in a large efficacy trial.

Malawi-Liverpool-Wellcome Trust clinical research programme

This is a major collaboration between University of Liverpool, Liverpool School of Tropical Medicine and University of Malawi College of Medicine. Professor Robert Heyderman is the Director of the programme.


www.mlw.medcol.mw/ ‎ 

Related projects

This work follows on from another MRF funded study in Malawi, which ended in 2010. Samples were collected from 1857 pregnant women to investigate the effect of HIV status on carriage of GBS bacteria. 

This current study will add to that collection by including paired samples from both mothers and their babies. The research team are interested in comparing the genetic fingerprints of this large collection with their collected samples. 

Since the charity was founded in 1989, we have awarded 161 research grants. The total value of our investment in vital scientific research is over £19.1 million (€24.7 million).
We take action that benefits people directly, including training health professionals and providing support and information services.
We call for positive change as a united voice against meningitis and septicaemia, and a dedicated champion for those it affects.
We've invested nearly £20 million into meningitis research since 1989. Now, we're looking back at our most incredible achievements so far.
Give researchers the clues to help defeat meningitis
Give researchers the clues to help defeat meningitis
£160/€190/$214 decodes the genetic information in a sample of meningococcal bacteria. This information helps us to track new forms of meningitis and campaign to introduce new vaccines.
Share this
Liz Rodgers
Research Officer

Hi, I’m Liz and I’m MRF's Research Officer.

If you’d like to know more about this area of MRF's work, do get in touch.

Tel: 0333 405 6258